SGLT-2 inhibition added to GLP-1 agonist therapy for type 2 diabetes: What is the benefit?

Zachary T. Bloomgarden, Yehuda Handelsman

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)1442-1444
Number of pages3
JournalEndocrine Practice
Volume21
Issue number12
DOIs
StatePublished - Dec 2015

Cite this